Obstructive sleep apnea (OSA) is a common condition that can cause daytime or nocturnal symptoms with long-term impact on the patient's health. Various therapies and surgeries have been introduced over the years, and patient wishes and compliance are essential factors in the success of treatment. Drug-induced sleep endoscopy (DISE) is a procedure that assesses the opening and closing of the upper airway in real time. This article summarizes the indications and contraindications of DISE, with a review of sedation methods and the VOTE classification system, in order to facilitate the use of a common nomenclature based on a protocol applied at the CHUV.
Le syndrome d'apnées obstructives du sommeil (SAOS) est une affection courante pouvant provoquer des symptômes diurnes ou nocturnes ayant un impact à long terme sur la santé du patient. Diverses thérapies et chirurgies ont été introduites au fil des années et les souhaits des patients et l'observance thérapeutique sont des facteurs essentiels dans le succès du traitement. L'endoscopie du sommeil induit par les médicaments (DISE: drug-induced sleep endoscopy) permet d'évaluer l'ouverture et la fermeture des voies respiratoires supérieures en temps réel. Cet article résume les indications et contre-indications de la DISE avec un rappel des méthodes de sédation et le système de classification VOTE, afin de faciliter l'utilisation d'une nomenclature commune basée sur un protocole appliqué au CHUV.
Anesthesia , Larynx , Humans , Endoscopy , Contraindications , Sleep
Hypoglossal nerve stimulation is an alternative treatment for obstructive sleep apnea syndrome (OSAS) in patients intolerant to CPAP. The INSPIRE system (unilateral hypoglossal nerve stimulation) available since 2014 and the NYXOAH system (bilateral hypoglossal nerve stimulation) available since 2019 help to treat OSAS via activation of the genioglossus muscle causing protrusion of the tongue during sleep. We present in this article the two types of hypoglossal nerve stimulators through a recent review of the literature.
La stimulation du nerf hypoglosse est un traitement alternatif du syndrome d'apnées obstructives du sommeil (SAOS) chez des patients intolérants à la CPAP (Continuous Positive Airway Pressure). Le système INSPIRE (stimulation unilatérale du nerf hypoglosse) disponible depuis 2014, et le système NYXOAH (stimulation bilatérale du nerf hypoglosse), disponible depuis 2019, permettent de traiter le SAOS via une activation du muscle génioglosse, provoquant une protrusion de la langue pendant le sommeil. Nous présentons dans cet article les 2 types de stimulateur du nerf hypoglosse à travers une revue récente de la littérature.
Electric Stimulation Therapy , Sleep Apnea, Obstructive , Humans , Hypoglossal Nerve/physiology , Sleep Apnea, Obstructive/therapy , Sleep/physiology , Continuous Positive Airway Pressure
Tooth autotransplantation is a procedure which provides the extraction of an erupted or impacted tooth and its repositioning to another site in the oral cavity. This Case Report describes a successful case of two autotransplantations of open-apex mandibular third molars in place of the hopeless first mandibular molars with the use of L-PRF in a growing patient. A 15-year-old male patient was referred to the Dental Clinic for the extractions of the two hopeless mandibular first molars. Autotransplantation was considered the best treatment option for both sites 36 and 46, because the presence of two impacted mandibular third molars (38 and 48) with an incomplete root formation. Teeth 36 and 46 were extracted and replaced with teeth 38 and 48. The patient had an uneventful healing. At follow-up visits, the two autotransplanted teeth showed physiologic mobility, absence of inflammation and discomfort, and absence of infection; probing depth values were within normal range, and the vitality tests were positive. After 2 years, the teeth in position 36 and 46 showed absence of infection and mobility, and positive pulp vitality tests and the radiographic examinations exhibited closure of the root apices as well as absence of any periapical radiolucency or root resorption. Tooth autotransplantation is a good treatment option in case of tooth loss offering an alternative to traditional or implant-supported prosthesis especially for growing patients.
Obstructive sleep apnea syndrome (OSAS) is a respiratory disorder affecting up to 49 % and 23 % of middle to older aged men and women respectively. CPAP (continuous positive airway pressure) is the gold-standard treatment for severe apneas. In mild and moderate forms of OSAS, mandibular advancement devices (MAD) are equally a first line of treatment. Both CPAP and MAD have their advantages and side effects. Patient tolerance to these two therapies varies according to different patient-parameters. In order to guide physicians and patients in choosing between these two treatments, we present a description of both treatment modalities.
Le syndrome d'apnées obstructives du sommeil (SAOS) est un trouble respiratoire du sommeil qui affecte jusqu'à 49 % des hommes et 23 % des femmes d'âge moyen à avancé. La ventilation en pression positive continue (CPAP) est actuellement le traitement de choix pour les cas sévères. Dans les stades léger et modéré de SAOS, l'orthèse d'avancement mandibulaire (OAM) est également un traitement que l'on peut proposer en première intention. La CPAP comme l'OAM ont leurs avantages et leurs inconvénients. La tolérance pour ces deux thérapies varie d'un patient à l'autre. Afin de guider le praticien et le patient dans le choix de ces deux traitements, nous proposons une description des deux modalités thérapeutiques.
Clinical Decision-Making , Continuous Positive Airway Pressure , Mandibular Advancement , Sleep Apnea, Obstructive/therapy , Continuous Positive Airway Pressure/adverse effects , Humans , Mandibular Advancement/adverse effects , Occlusal Splints/adverse effects
The management of patients under treatment with Direct Oral Anticoagulants (DOACs) has led clinicians to deal with two clinical issues, such as the hemorrhagic risk in case of non-interruption or the risk of thromboembolism in case of suspension of the treatment. The primary aim of this retrospective study was to evaluate the incidence of perioperative bleeding events and healing complications in patients who were under treatment with Rivaroxaban and who received dental implants and immediate prosthetic restoration. Patients treated with Rivaroxaban (Xarelto 20 mg daily) and who needed implant rehabilitation were selected. Four to six implants were placed in mandibular healed sites or fresh extraction sockets. All patients, in agreement with their physicians, interrupted the medication for 24 h and received implants and immediate restorations. Twelve patients and 57 implants were analyzed in the study. No major postoperative bleeding events were reported. Three patients (25%) presented slight immediate postoperative bleeding controlled with compression only. The implant and prosthetic survival rate were both 100% after 1 year. Within the limitations of this study, multiple implant placement with an immediate loading can be performed without any significant complication with a 24 h discontinuation of Rivaroxaban, in conjunction with the patient's physician.
Immediate Dental Implant Loading , Rivaroxaban/therapeutic use , Aged , Aged, 80 and over , Dental Restoration Failure , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Rivaroxaban/adverse effects , Tooth Extraction , Tooth Socket/surgery , Treatment Outcome
OBJECTIVE: The purpose of this retrospective study was to assess the influence of antibiotics on the development of alveolitis after tooth extractions. MATERIALS AND METHODS: The study population consisted of patients who had erupted tooth extractions in 3 centers. The patients' medical records were collected for several parameters. Moreover, use of antibiotics was evaluated. The primary outcome was the development of alveolitis during the postoperative period. The secondary outcome measure was the possible associations between alveolitis and other patients' characteristics. RESULTS: A total of 1579 patient charts were screened. The patients enrolled in the study were 418 (159 males and 259 females). Alveolitis was reported for 12 extraction sites (2.87%). Six were in the group of patients that received antibiotics (2.14% out of 280 patients treated with antibiotics), and six were in the group of patients that did not receive antibiotics (4.35% out of 138 patients not receiving antibiotics). None of patient-level parameters showed any significant association with the development of alveolitis. CONCLUSION: In conclusion, this study showed that the use of antibiotics after erupted tooth extractions is not useful in preventing alveolitis. Larger, prospective, and randomized studies are needed before incorporating these findings into the daily clinical practice.
Anti-Bacterial Agents , Tooth Extraction , Anti-Bacterial Agents/therapeutic use , Female , Humans , Lung Diseases/prevention & control , Male , Prospective Studies , Retrospective Studies , Tooth Extraction/adverse effects
Medication-related osteonecrosis of the jaw are bone exposures in the maxillofacial region that does not heal after 8 weeks from the observation of a health care provider in patients with history of the intake of antiresorptive agents and no previous irradiation of the craniofacial region. Initially attributed only to the intake of bisphosphonates they have later been associated also with the intake of other classes of antiresorptive medications.This retrospective study analyzed records from patients with documented medication-related osteonecrosis of the jaws treated in our unit. Clinical data, comorbidities and concurrent medications, treatment outcome information such us number of repeated treatments needed, antibiotic used, type of treatment adopted were recorded. Baseline demographics for the included records of 15 patients (mean age: 64 years) revealed a treatment success rate of 73.3% (mean observation period: 42.2 months), failure rate of 26.6%, dental extraction trigger rate of 33.3%, and a spontaneous trigger rate of 40%.Zolendronate and denosumav were the medications most frequently associated with the upset of medication-related osteonecrosis of the jaw (60% of the sample). In 8 cases out of the 11 that were successful, the surgical treatment had to be repeated more than once. Leukocyte-platelet-rich fibrin led to the resolution of 11 of the 14 cases in which it was used.
Bisphosphonate-Associated Osteonecrosis of the Jaw/therapy , Platelet-Rich Fibrin , Aged , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Humans , Middle Aged , Retrospective Studies , Treatment Failure
Isolated congenital vomer agenesis is a very rare and poorly understood condition. In the context of dental work-up by cone-beam computed tomography (CBCT), the explored volume of the facial bones occasionally reveals incidental abnormalities. We report the case of a 13-year old Caucasian female who underwent CBCT for the pre-treatment evaluation of primary failure of tooth eruption affecting the permanent right upper and inferior molars. CBCT depicted a large defect of the postero-inferior part of the nasal septum without associated soft tissue abnormality and without cranio-facial malformation or cleft palate. In the absence of a history of trauma, chronic inflammatory sinonasal disease, neoplasia and drug abuse, a posterior nasal septum defect warrants the diagnosis of vomer agenesis. A discussion of this condition and of salient CBCT features is provided.
